These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11828780)

  • 21. Clinical experience of sirolimus-eluting stents in patients with coronary artery disease at Bangkok Heart Institute.
    Lolekha P; Bhuripanyo K; Kukreja R; Mahanonda N; Numee M
    J Med Assoc Thai; 2003 May; 86 Suppl 1():S76-82. PubMed ID: 12866772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Access to investigational treatments.
    Ader M
    Health Matrix Clevel; 1996; 6(1):187-99. PubMed ID: 10167167
    [No Abstract]   [Full Text] [Related]  

  • 23. [Past, present, and future of intracoronary brachytherapy].
    Angiolillo DJ; Sabaté M
    Ital Heart J Suppl; 2003 Oct; 4(10):794-806. PubMed ID: 14664291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment and prevention of restenosis after percutaneous coronary intervention. Balloons, stents, radioactive rays and drug-releasing stents].
    Maeng M; Thuesen L; Andersen HR
    Ugeskr Laeger; 2005 Aug; 167(33):3030-2. PubMed ID: 16109244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Will insurers pay for high-tech care?
    Crane M
    Med Econ; 1991 Apr; 68(8):82-6. PubMed ID: 10110091
    [No Abstract]   [Full Text] [Related]  

  • 26. XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent.
    Beijk MA; Piek JJ
    Expert Rev Med Devices; 2007 Jan; 4(1):11-21. PubMed ID: 17187467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effective and efficient strategies for coronary revascularization in the drug-eluting stent era.
    Lepor NE; Madyoon H; Kereiakes D
    Rev Cardiovasc Med; 2002; 3 Suppl 5():S38-50. PubMed ID: 12478234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of the introduction of drug-eluting stents on the clinical practice of surgical and percutaneous treatment of coronary artery disease.
    van Domburg RT; Lemos PA; Takkenberg JJ; Liu TK; van Herwerden LA; Arampatzis CA; Smits PC; Daemen J; Venema AC; Serruys PW; Bogers AJ
    Eur Heart J; 2005 Apr; 26(7):675-81. PubMed ID: 15637087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Defining experimental therapy--a third-party payer's dilemma.
    Newcomer LN
    N Engl J Med; 1990 Dec; 323(24):1702-4. PubMed ID: 2233969
    [No Abstract]   [Full Text] [Related]  

  • 30. Coronary artery restenosis: vascular biology and emerging therapeutic strategies.
    Sarkar K; Sharma SK; Sachdeva R; Romeo F; Garza L; Mehta JL
    Expert Rev Cardiovasc Ther; 2006 Jul; 4(4):543-56. PubMed ID: 16918273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vascular brachytherapy: applications in the era of drug-eluting stents.
    Waksman R
    Rev Cardiovasc Med; 2002; 3 Suppl 5():S23-30. PubMed ID: 12478232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Managing the introduction of expensive medical procedures: use of a registry.
    Grilli R; Taroni F
    J Health Serv Res Policy; 2006 Apr; 11(2):89-93. PubMed ID: 16608583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recurrent restenosis after implantation of sirolimus-eluting stents in aorto-ostial lesions: successful treatment with polytetrafluoroethylene-covered stents.
    Gagnor A; Varbella F; Rubartelli P; Luceri S; Conte MR
    J Cardiovasc Med (Hagerstown); 2008 Feb; 9(2):201-4. PubMed ID: 18192816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A changing paradigm in the study and adoption of emerging health care technologies: coverage with evidence development.
    Wallner PE; Konski A
    J Am Coll Radiol; 2008 Nov; 5(11):1125-9. PubMed ID: 18954812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative clinical outcomes of paclitaxel- and sirolimus-eluting stents: results from a large prospective multicenter registry--STENT Group.
    Simonton CA; Brodie B; Cheek B; Krainin F; Metzger C; Hermiller J; Juk S; Duffy P; Humphrey A; Nussbaum M; Laurent S;
    J Am Coll Cardiol; 2007 Sep; 50(13):1214-22. PubMed ID: 17888837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coronary endothelial dysfunction following sirolimus-eluting stent placement: should we worry about it?
    Lerman A; Eeckhout E
    Eur Heart J; 2006 Jan; 27(2):125-6. PubMed ID: 16278231
    [No Abstract]   [Full Text] [Related]  

  • 37. Drug-eluting stents for in-stent restenosis and acute myocardial infarction: present data from nonrandomized studies.
    Schofer J; Bode C; Silber S
    Herz; 2004 Mar; 29(2):195-200. PubMed ID: 15057441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Is systematic use of drug-eluting stents justified? Arguments against].
    Macaya C
    Rev Esp Cardiol; 2004 Feb; 57(2):109-15. PubMed ID: 14967105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence and predictors of target vessel revascularization and clinical event rates of the sirolimus-eluting coronary stent (results from the prospective multicenter German Cypher Stent Registry).
    Zahn R; Hamm CW; Schneider S; Zeymer U; Nienaber CA; Richardt G; Kelm M; Levenson B; Bonzel T; Tebbe U; Sabin G; Senges J;
    Am J Cardiol; 2005 Jun; 95(11):1302-8. PubMed ID: 15904633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The pathophysiology and burden of restenosis.
    Weintraub WS
    Am J Cardiol; 2007 Sep; 100(5A):3K-9K. PubMed ID: 17719351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.